Alumis (ALMS) Change in Accured Expenses (2023 - 2025)
Alumis (ALMS) reported Change in Accured Expenses of $3.5 million for Q4 2025, up 11.75% year-over-year from $3.1 million in Q4 2024, and up 187.42% on a QoQ basis from -$4.0 million in Q3 2025.
Alumis (ALMS) has 3 years of Change in Accured Expenses data on file, last reported at $3.5 million in Q4 2025.
- Quarterly Change in Accured Expenses rose 11.75% year-over-year to $3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.0 million (up 70.41% YoY) and the FY2025 annual result came in at $6.0 million, up 70.41% from the prior year.
- Change in Accured Expenses rose to $3.5 million in Q4 2025 per ALMS's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.0 million in Q1 2025 and bottomed at -$4.0 million in Q3 2025.
- The 3-year median for Change in Accured Expenses is $1.6 million (2023), against an average of $1.2 million.
- Peak annual rise in Change in Accured Expenses reached 255.29% in 2025, while the deepest fall reached 270.36% in 2025.
- Tracing ALMS's Change in Accured Expenses over 3 years: stood at $1.6 million in 2023, then soared by 91.64% to $3.1 million in 2024, then rose by 11.75% to $3.5 million in 2025.
- Per Business Quant, the three latest ALMS Change in Accured Expenses figures stand at $3.5 million (Q4 2025), -$4.0 million (Q3 2025), and $1.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | 3.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.48 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.55 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Mar 31, 2025 | 4.99 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Dec 31, 2024 | 3.12 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | -3.21 Mn |
| Mar 31, 2024 | -3.21 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |